免疫性血小板減少症（ITP）- 疫学予測 2028年
Immune Thrombocytopenia (ITP) - Epidemiology Forecast - 2028
|発行||DelveInsight Business Research LLP||商品コード||915396|
|出版日||ページ情報||英文 84 Pages
|免疫性血小板減少症（ITP）- 疫学予測 2028年 Immune Thrombocytopenia (ITP) - Epidemiology Forecast - 2028|
|出版日: 2019年11月01日||ページ情報: 英文 84 Pages||
DelveInsight's 'Immune Thrombocytopenia (ITP)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Immune Thrombocytopenia (ITP) Infections in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Most of children with newly diagnosed ITP will develop chronic disease. Because of the high impact of ITP on a child's everyday life and activities, as well as to decide whether treatment has to be instituted to influence the clinical course of ITP, it is of clinical significance if the course of the disease could be predicted at time of diagnosis.
Our forecasting model has defined the prevalent population of Chronic Immune Thrombocytopenia (ITP) in children & adults. Chronic ITP patient inclusive of both primary ITP and secondary ITP. Approximately 70-75% of patient are refractory to first line therapies (corticosteroids/IVIG & others) and take second line therapies. As per the analysis, we have found that approximately 60-65% patients are refractory to second line treatment and take third line treatment.
Study Period: 2017-2028
Immune thrombocytopenia (ITP) - Disease Understanding
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function.
Immune thrombocytopenia (ITP) is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, Total Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, and Gender-specific Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM) scenario of Immune thrombocytopenia (ITP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total prevalent population of Immune Thrombocytopenia (ITP) in 7 major markets ranges from 180,498 in 2017. The number of Immune thrombocytopenia (ITP) cases in the 7MM is expected to increase during the study period of 2017-2028.
In addition, in 7MM, the total diagnosed prevalent cases is 147,174 in 2017. These cases are increased during study period (2017-2028).
In 2017, there were total 53,362 diagnosed prevalent cases of Immune thrombocytopenia (ITP) in the United States. Assessments as per DelveInsight's analysts show that the total diagnosed prevalent cases of Immune thrombocytopenia (ITP) are subjected to increase. Out of the total diagnosed cases, 49,640 cases account for adult ITP and 3,723 cases were diagnosed prevalence population in children in 2017.
Among the European countries, United Kingdom had the highest prevalent population of Immune thrombocytopenia (ITP) with 26,274 cases, followed by Italy which had a prevalent population of 18,604 in 2017. On the other hand, Spain had the lowest prevalent population of 12,207 in 2017.